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1105-78 Angiogenlc Growth Factors Expression of In-Vivo 
Human Aortic Endothelial Cells Within Gas-Plasma 
Treated Implants 
Oscar C. Munoz, Jodie Polan, Nilesh Goswami, Mauli Agrawal, Staven Bailey, University 
of Texas Health Science Center at San Antonio, San Antonio, Texas. 
Background: Ischemia induces expression of angiog6nic proteins such as Vascular 
Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF). VEGF is 
essential in initiating endothelial migration, stimulating the release of other growth factors 
and inducing neovasculadzation (angiogenesis). We previously demonstrated in our lab- 
oratory that gas-plasma treated bioresorbable poly-D, L-lectide acid implants seeded 
with Human aortic endothelial cells (HAECs) promote in vivo angiogenesis in athymic 
nude mouse model. 
Materlala and Methods: HAECs seeded at a density of 3x104 were incubated in gas- 
plasma treated implants for 6 days. Implants were positioned in the omentum of 17-22 
grn nude (N= 115) grouped into shams (n=7), both control and treated implants with and 
without HAECs (n=27 per group). Animals were sacrificed at days 12, 18, 24 and 72. 
Implants, omentum and adjacent skin were sampled. Laser confecal micrographs were 
used to determine the apparent surface areas per endothelial cell expressing either fluo- 
rescent VEGF conjugated to Alexa 546 (CY5) or bFGF using (PeproTech) mouse antihu- 
man monoclonal antibody conjugated to IgG-CY3 (Sigma; EXC552/EM565). Data was 
analyzed using ImagePro, EXCEL and Sigma Plot. Both T test and linear regressions 
were performed. 
Results: VEGF and bFGF were found in endothelial cells located in and around the 
implant. The surface area of HAECs expressing VEGF within Control and Treated 
implants were significantly different : 92 ± 41.9 vs. 221± 83.5 (arbitrary units), p=0.0001 
and r2=0.00714. Similar results were found for HAECs expressing bFGF. 
Conclusions: VEGF and bFGF enhancement of transplanted HAECs in gas-plasma 
treated implants provide a cell-based mechanism of enhanced angiogenesis in our in 
vivo nude mouse model 
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1106-79 Enoxaparin Versus Heparin in Patients Receiving 
Ept l f lbat ide  
Daniel D. Gretler, Leese 1". Phillip, Kealy A. Jennifer, Kitt M. Michael, COR Therapeutics 
/nc, South San Francisco, California, Quinti/es, Inc., Lenexa, Kentucky. 
GPIIb/llla inhibitor trials have been conducted with the coadministration of unfrectionatad 
heparin (UFH). However, low molecular weight hepadns (LMWH) are being used 
increasingly in clinical practice. To examine the appropriateness of substituting enox- 
apadn (Eno) for UFH in patients treated with aptifibattde (Ept), the PK and PD properties 
of Ept were examined with Eno versus UFH in a randomized, two-way crossover study in 
14 men and women ages 45 to 60. Drug regimens were administered for 48 h as follows: 
Ept 180 tlg/kg iv bolus and 2 pg/kg-min infusion plus either UFH 5000 IU IV bolus and 
1000 U/h infusion or Eno 1 mg/kg sc q12h. 
Results: Figure 1 depicts Ept plasma concentrations and platelet aggregation over time. 
Ept plasma concentrations decreased transiently between 1 and 4 hours, which is pre- 
vented by the addition of a second 180 pg/kg bolus, as used in the ESPRIT trial. Levels 
were virtually identical regardless of the administration of Eno versus UFH with steady- 
state mean±SD values (1610±229 ng/mL versus 1640±227 ng/mL; p=0.408). Ex vivo 
platelet aggregation induced by 20 pM ADP was almost completely inhibited at all time 
points with both regimens (2±4% and 3¢6% at staady-state; p=0.937). Lastly, estimates 
for mean±SE IC50 for Ept were very similar regardless of Eno versus UFH administration 
( 171± 16 and 174±16 ng/mL, respectively). 
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Conclusions: The substitution of Eno for UFH does not affect the plasma concentrations 
of Ept or the level of platelet aggregation inhibition achieved at any time point. 
1106-80 A Prospective and Randomized Compar i son  o f  Low 
Molecular Weight Heparln and Unfractioned Heparln in 
Chronically Anticoagulated Patients Prior to Cardiac 
Catheter i zat ion  
Hevder Omran, Chdstoph Hammerstingl, Harald Schmidt, Bemdt L~dedtz, University of 
Bonn, Bonn, Germany 
Background: It is recommended to discontinue oral anticoagulation (OAC) prior to car- 
diac cathatedzation in chronically anticoagulated patients (pts). To prevent thromboem- 
bolic complications pts should receive intermittent herapy with unfractionatad heparin 
(UH). Low molecular weight heparins (LMWH) have a higher bioavailability and more 
predictive anticoagulatory effect than UH. The aim of this prospective randomized trial 
was to compare the effectiveness of enoxaparin and UH for achieving anticoagulation 
prior to cardiac catheterization in OAC pts. 
Methods: Consecutive chronically anticoagulated pts with either atrial fibrillation and / or 
mechanical heart valves were included in the study. Pts were randomized to receive 
either weight adapted enoxaparin s.c. 2 times per day or weight adapted intravenous UH. 
Cardiac procedures were performed at an INR < 1.5. The activated PTr (effective: 1.5 to 
2.5 x the control value) and anti-Xa activity was measured daily (effective: 0.5-1.0 IU/ml). 
The primary endpoint of the study was the time (days) until effective anticoagulation was 
achieved under both treatment strategies. The secondary endpoint was the percent of 
days of ineffective treatment. 
Results: 27 pts were treated with enoxaparin and 26 patients with UH. The groups did not 
differ for age, sex, left ventricular ejection fraction and distribution for the indication of 
OAC. The time until effective anticoagulation was achieved was significantly shorter in 
the enoxaparin group as compared to the UH group (1.3 ± 0.6 versus 3.0 ± 2.1 days, 
P=0.008). Furthermore, the percentage of days with ineffective anticoagulation therapy 
was signficantly lower in the enoxaparin group than in the UH group (11.9 ± 20.8 versus 
43.2 ± 27.3 %, P=0.004) 
Conclusions: Low molecular weight hepadn (enoxapadn) is superior to unfractionated 
heparin for achieving more rapid and constant effective anticoagulation therapy in chron- 
ically anticoagu[atad patients prior to cardiac catheterization. 
1106-81 Interference With Point-of-Care INR De~erminatlons: 
Effect of Heparin and Low Molecular Weight Heparin on 
Multiple Point-of-Care Coagulometers 
Alan K. Jacobson, Myra Petarson, Tiffany Gunneman, Phil Ng, James Westengard, 
Lvnne Ruvbalid, Loma Linda VA Medical Center, Loma Linda, California, Loma Linda 
Universi~ Loma Linda, California. 
Background: The increased use of low molecular weight heparin preparations has 
occurred at the same time that point-of-care (POC) prothrombin time testing by patients 
and professionals has increased, raising concerns as to the accuracy of POC INR deter- 
minations in patients receiving low molecular weight heparin. 
Methods: To evaluate the magnitude of interference, 60 patients on chronic warfadn ther- 
apy underwent baseline INR testing involving the simultaneous dosing of 24 POC INR 
devices representing 10 unique coagulometer technologies from 4 companies (Roche, 
International Technidyne, Avocet, Lifescan). Patients then received a single therapeutic 
intensity dose of subcutaneous hepadn, enoxaparin, daltepadn, or tinzaparin and under- 
went repeat INR testing on all devices at one and three hours after administration result- 
ing in 40 subsets of devices and heparin preparations for evaluation. 
Results: Baseline INR values ranged from 1.3 to 5.4 and significant elevations were seen 
by one hour which increased further by throe hours. The average INR increase 3 hours 
post dose for enoxaparin was 0.35 INR, 0.46 INR for unfractionated heperin, 0.72 INR 
for daltepedn and 1.11 INR for tinzapadn. However, the effect on individual coagulome- 
ters was also quite variable (see table). 
Conclusion: There is potential for clinically significant interference in INR determinations 
obtained by POC devices in the presence of heparin preparations in the first several 
hours following subcutaneous administration. 
Magnitude end Frequency of INR Shift 
Amount of INR Shift From 0.0- 0.25 0.26- 0.50 0.51 - 0.75 0.76- t.00 >f.00 
Baseline 
Number of Systems 10 11 5 5 10 
1106-82 Magnitude of INR Variation Attributable to Differences 
Between Point-of-Care Prothrombin Time Testing 
Devices 
Alan K. Jacobson. Myra Peterson, Tiffany Gunneman, Jim Westengard, Lynne Ruybalid, 
Loma Linda VA Medical Center, Loma Linda, California, Loma Linda University, Loma 
Linda, California. 
The tNR system for the reporting of the prothrombin time test was intended to minimize 
the variation in test results between different esting systems. Limitations of the INR sys- 
tem have previously been demonstrated for central lab instrumentation and reagents. 
Evaluation of INR variability due to POC device specific characteristics was undertaken 
as a substudy to a larger project evaluating heparin interference with POC INR determi- 
nations. Methods: 60 patients on chronic warfarin therapy underwent venipuncturo acqui- 
sition of a whole blood sample which was tested on 24 devices representing 10 unique 
technologies from 4 companies (Roche, International Technidyne, Avocet, Ufescan). A 
technology was classified as unique based on endpoint detection methodology, interpre- 
tation algorithm, and thromboplastin sensitivity. 
Results: Mean INR values ranged from 1.3 to 5.4 with the majority of the values (42) 
being between 2 and 3. Significant differences were seen when the INR results were 
compared across the 10 technologies represented. Even within the therapeutic range the 
variation in INR was significant in that a patient with a mean INR of 2.5 was found to have 
